Clearmind Medicine (NASDAQ:CMND) Major Shareholder Financial Lp Hrt Sells 225,191 Shares

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 225,191 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $0.12, for a total value of $27,022.92. Following the completion of the transaction, the insider owned 1,838,075 shares of the company’s stock, valued at approximately $220,569. The trade was a 10.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, June 10th, Financial Lp Hrt bought 2,159,052 shares of Clearmind Medicine stock. The stock was purchased at an average price of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Price Performance

NASDAQ:CMND remained flat at $3.34 during trading hours on Friday. The company’s stock had a trading volume of 160,621 shares, compared to its average volume of 1,154,189. The firm has a 50-day moving average price of $6.37 and a 200-day moving average price of $17.01. The firm has a market capitalization of $3.40 million, a PE ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a 1-year low of $2.10 and a 1-year high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.